October 25, 2018 | Chip Kahn
Category: Financing, Medicare, Pharmaceuticals
We agree with the President that it is time to reduce the drug tab for Americans, and actions need to be focused on the real culprit - manufacturers’ prices - not the frontline hospitals and physicians who administer and prescribe those medicines. We look forward to examining the details and fine print of the Administration’s proposals.
It is important that the plan aim at protecting patients and does not impede the freedom of physicians to prescribe the precise drug therapies their patients need.
- New Report Shows Impact of Rising Drug Prices and Drug Shortages on Patients and Hospitals
- FAH Leader Expresses Opposition to Ruling that Overturns 340B Medicare Regulation
- FAH, AHA Send Joint Letter to Congress on Surprise Billing
- FAH Comments on Proposed Rule Expanding Use of HRAs